CKPT Checkpoint Therapeutics
- 2.100
- -0.050-2.33%
- 2.140
- +0.040+1.90%
Checkpoint Therapeutics News
Checkpoint Therapeutics | EFFECT: Others
Checkpoint Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Checkpoint Therapeutics | 10-Q: Q2 2024 Earnings Report
Checkpoint Therapeutics | 8-K: Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
Checkpoint Therapeutics | 8-K: Current report
Checkpoint Therapeutics | D: Filing D
Checkpoint Therapeutics | 8-K: Current report
Checkpoint Therapeutics | 424B5: Prospectus
Checkpoint Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Oliviero James F III
Checkpoint Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer GRAY WILLIAM GARRETT
Checkpoint Therapeutics | 8-K: Current report
Checkpoint Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer GRAY WILLIAM GARRETT
Checkpoint Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Oliviero James F III
Checkpoint Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Checkpoint Therapeutics | 3: Initial statement of beneficial ownership of securities-10% Owner Fortress Biotech, Inc.
Checkpoint Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Fortress Biotech, Inc.(11.2%)
Checkpoint Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director WEISS MICHAEL S
Checkpoint Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Amit Sharma
Checkpoint Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SALZMAN BARRY M
Checkpoint Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director ROSENWALD LINDSAY A MD
Analysis
Price Target
No Data
